Zealand’s SBS drug shows promising phase II results
Zealand Pharma’s candidate drug glepaglutide has met the primary endpoint in a phase II study testing it as a treatment of short bowel syndrome (SBS). Phase III trials can begin next year.
BY MARTIN HAVTORN PETERSEN
The Danish biotech company Zealand Pharma delivers a steady flow of positive clinical results these days and the company has now announced promising phase II data for the candidate drug glepaglutide.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand CEO: cancelled agreement is positive news
For abonnenter
Partner gives up rights to potential Zealand drug
For abonnenter
